Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

HemCon Medical Technologies, Inc., an innovative developer of advanced medical products, is proud to announce the signing of an exclusive licensing agreement with Zeria Pharmaceuticals Co. Ltd., a leading pharmaceutical and consumer healthcare products company. Through this partnership, Zeria will market, distribute, and sell HemCon's line of revolutionary wound and oral care dressings throughout Japan.

9 Apr 2010

Recql5 identified as a tumor suppressor in GI tract

Recql5 is a member of the mammalian RecQ helicase family. Genetic mutations that result in loss of RecQ helicase activity give rise to disorders that are associated with cancer predisposition and premature aging, such as Bloom, Werner, and Rothmund-Thomson syndromes. This class of enzymes is best known for their role in maintaining the integrity of the genome to prevent oncogenic mutations.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

EndoChoice, Inc. announced today that it has acquired Pathworks Anatomic Pathology Laboratory. Founded in 1989, Pathworks is a College of American Pathologists (CAP) accredited national reference laboratory located in Atlanta, GA. Robert Smith, MD, founder of the laboratory, will assume the Medical Director position of EndoChoice Pathology, a wholly-owned subsidiary of EndoChoice, Inc.

8 Apr 2010

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

8 Apr 2010

Women living in northeastern U.S. more likely to develop RA: Study

Women living in the northeastern United States are more likely to develop rheumatoid arthritis, suggesting a link between the autoimmune disease and vitamin D deficiency, says a new study led by a Boston University School of Public Health researcher.

8 Apr 2010

Torax Medical's LINX Anti-Reflux treatment receives CE Mark approval

Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease (GERD), has received CE Mark for its LINX® Anti-Reflux treatment. The company has started commercial launch of the LINX device at select centers in Europe.

8 Apr 2010

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

New clinical algorithms will give physicians a practical, efficient and cost-effective aid to diagnose the frequent gastrointestinal symptoms that patients commonly bring to their primary care doctors and gastroenterologists--symptoms of functional GI disorders that are often difficult to diagnose.

7 Apr 2010

FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

Baxter International Inc. and Nycomed today announced the U.S. Food and Drug Administration (FDA) approval of TachoSil (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only adjunctive hemostatic agent available in the U.S. that combines a collagen patch with a coating of human coagulation factors.

From Baxter International Inc. 7 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

5 Apr 2010

Side effects may limit use of Prometheus's Lotronex for IBS

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.

5 Apr 2010

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.

5 Apr 2010

Warner Chilcott, sanofi-aventis amend Actonel global collaboration agreement

Warner Chilcott plc and sanofi-aventis announced today an amendment to the Actonel® global collaboration agreement with respect to the parties' arrangement in the United States and Puerto Rico. Under the terms of the amendment, Warner Chilcott will take full operational control over the promotion, marketing and R&D decisions for Actonel in the United States and Puerto Rico, and will assume responsibility for all associated costs relating to those activities.

5 Apr 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Zeria to market, distribute, and sell HemCon's wound and oral care dressings in Japan

Recql5 identified as a tumor suppressor in GI tract

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Parents lack understanding of causes, signs and symptoms of dehydration in children

EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Women living in northeastern U.S. more likely to develop RA: Study

Torax Medical's LINX Anti-Reflux treatment receives CE Mark approval

Rome Foundation develops Diagnostic Algorithms to diagnose GI symptoms

FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Side effects may limit use of Prometheus's Lotronex for IBS

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Warner Chilcott, sanofi-aventis amend Actonel global collaboration agreement

Rebirth of the cursed drug Thalidomide

Microbiology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in